TITLE

Lycopene lowers PSA in prostate cancer patients

AUTHOR(S)
Holzman, David
PUB. DATE
January 2002
SOURCE
Life Extension;Jan2002, Vol. 8 Issue 1, p25
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Details study findings showing that lycopene lowers prostate specific antigen in prostate cancer patients. Evidence indicating that high concentration of lycopene in prostate tissues resulted in an increase in programmed cell damage among cancer cells; Prospective studies showing that men who eat lots of tomato sauce have a lower risk of prostate cancer than men who do not.
ACCESSION #
6925720

 

Related Articles

  • Prostate cancer. Dhami, Sangeeta // GP: General Practitioner;9/23/2002, p51 

    Provides information related to prostate cancer. Risk factors associated with the condition; Investigation on the elevated prostate-specific antigen levels; Use of radiotherapy as an alternative treatment.

  • PSA screening: The controversy that refuses to die. Rahman, Nadeem // Business Journal Serving Fresno & the Central San Joaquin Valley;10/14/2011, p26 

    The author discusses the controversies surrounding the prostate-specific antigen (PSA) screening in the U.S. that has provided a dramatic change in the presentation of the disease since its widespread use.

  • Value of PSA screening brought into question again. Dosa, Laszlo // Urology Times;Jul2002, Vol. 30 Issue 7, p4 

    Describes a study conducted in Canada revealing that no definite association can be found between prostate-specific antigen (PSA) screening and prostate cancer mortality rates. Data showing that a greater increase in prostate cancer incidence does not necessarily indicate a greater decline in...

  • Man with early PCa could benefit from delayed therapy.  // Urology Times;Jul2002, Vol. 30 Issue 7, p40 

    Reveals that prostate-specific antigen is a poor marker of the progression of prostate cancer.

  • FDA may rely on biomarkers to evaluate new PCa devices. Carlson, Robert H. // Urology Times;Feb2003, Vol. 31 Issue 2, p21 

    Focuses on the use of prostate-specific antigen biomarkers in determining the efficacy of devices used in treating prostate cancer in Paris, France. Accounts on the beam radiation, brachytherapy and cryotherapy devices approved by the Food and Drug Administration; Efficacy of ultrasound and...

  • PSA doubling time: Solid predictor of PCa survival. Prescott, Lawrence M. // Urology Times;Aug2004, Vol. 32 Issue 11, p13 

    Reports that prostate specific antigen (PSA) doubling time seems to be a predictor of the probability of distant metastasis and prostate-cancer specific survival in men with biochemical relapse after radical prostatectomy, according to a study conducted by researchers from Baltimore, Maryland....

  • Abstracts: S29-S36.  // Prostate Cancer & Prostatic Diseases;2002 Supplement 1, Vol. 5 Issue 1, pS29 

    Prostate Cancer and Prostatic Diseases (2002) 5, S29–S36. doi:10.1038/sj.pcan.4500596

  • PSA velocity may not contribute to prostate cancer screening process.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p20 

    The article reports that inclusion of prostate specific antigen (PSA) velocity did not improve the predictive precision of prostate cancer screening significantly, which is based on a study on the prostate cancer detection guidelines of the American Urological Association in the U.S.

  • Right role for PSA screening difficult to define. Haris, Jason // Hem/Onc Today;4/10/2011, Vol. 12 Issue 7, p1 

    The article focuses on the views of experts with regards to the benefits and disadvantages of prostate specific antigen (PSA) for prostate cancer screening.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics